Page last updated: 2024-08-03 18:25:34
isoascorbic acid
Description
isoascorbic acid: food antioxidant; (L)-isomer is ascorbic acid; RN given refers to (D)-isomer; structure [MeSH]
D-isoascorbic acid : no description available [CHeBI]
Cross-References
ID Source | ID |
PubMed CID | 54675810 |
CHEMBL ID | 486293 |
SCHEMBL ID | 18678 |
SCHEMBL ID | 3700961 |
CHEBI ID | 51438 |
MeSH ID | M0046353 |
Synonyms (95)
Synonym |
d-erythro-hex-2-enonic acid gamma-lactone |
CHEBI:51438 , |
d-erythro-hex-2-enono-1,4-lactone |
e315 |
CHEMBL486293 |
isoascorbic acid |
erythorbic acid |
saccharosonic acid |
araboascorbic acid |
d-erythro-hex-2-enonic acid, .gamma.-lactone |
isovitamin c |
89-65-6 |
erycorbin |
neo-cebicure |
d-araboascorbic acid |
glucosaccharonic acid |
d-ascorbic acid, iso |
nsc-8117 |
d-erythorbic acid |
d-isoascorbic acid |
(5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5h)-one |
einecs 201-928-0 |
2,3-didehydro-d-erythro-hexono-1,4-lactone |
ccris 6568 |
fema no. 2410 |
erythroascorbic acid, d- |
d-erythro-3-oxohexonic acid lactone |
d-erythro-3-ketohexonic acid lactone |
brn 0084271 |
hsdb 584 |
fema number: 2410 |
3-keto-d-erythro-hexonic acid gamma-lactone |
3-oxohexonic acid lactone, d-erythro- |
hex-2-enonic acid gamma-lactone, d-erythro- |
nsc 8117 |
d-erythro-hex-2-enonic acid, gamma-lactone, |
mercate 5 |
d-isoascorbic acid, >=99%, fcc, fg |
d-(-)-isoascorbic acid, 98% |
1F9G |
7179C406-7CCF-4C07-9125-AA71E28FB983 |
A0520 |
A843272 |
ec 201-928-0 |
erythorbic acid [nf] |
unii-311332oii1 |
5-18-05-00026 (beilstein handbook reference) |
311332oii1 , |
NCGC00258663-01 |
tox21_201111 |
dtxcid306537 |
cas-89-65-6 |
dtxsid6026537 , |
C20364 |
AKOS015856346 |
(r)-5-((r)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5h)-one |
isoascorbic-acid |
ins-315 |
ins no.315 |
erythorbic acid [mart.] |
isoascorbic acid [mi] |
e-315 |
erythorbic acid [fhfi] |
d-erythro-hex-2-enoic acid gamma-lactone |
erythorbic acid [inci] |
ascorbic acid impurity f [ep impurity] |
erythorbate |
erythorbic acid [ii] |
erythorbic acid [fcc] |
(5r)-5-((1r)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5h)-one |
erythorbic acid [hsdb] |
erythorbic acid [usp-rs] |
SCHEMBL18678 |
SCHEMBL3700961 |
d-(-)-isoascorbic acid |
J-506944 |
mfcd00005378 |
erythorbic acid, united states pharmacopeia (usp) reference standard |
(5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5h)-one (d-isoascorbic acid); ascorbic acid impurity f; sodium ascorbate impurity f |
(5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5h)-one (non-preferred name) |
(2r)-2-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one |
Q424531 |
d-erythro-hex-2-enoic acid ?-lactone |
Z1255372411 |
d-iso-ascorbic acid |
HY-N7079 |
CS-0014152 |
d-erythro-hex-2-enonic acid, g-lactone |
AC8021 |
d-isoascorbic acid 1000 microg/ml in acetonitrile |
d(-)-isoascorbic acid (erythorbic acid) |
d-soascorbic acid |
(5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5h)-one (d-isoascorbic acid) |
EN300-251979 |
(5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one |
Drug Classes (1)
Pathways (1)
isoascorbic acid is involved in 1 pathway(s), involving a total of 0 unique proteins and 466 unique compounds
Protein Targets (3)
Potency Measurements
Inhibition Measurements
Bioassays (2)
Research
Studies (167)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 59 (35.33) | 18.7374 |
1990's | 34 (20.36) | 18.2507 |
2000's | 35 (20.96) | 29.6817 |
2010's | 25 (14.97) | 24.3611 |
2020's | 14 (8.38) | 2.80 |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 3 (1.70%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 173 (98.30%) | 84.16% |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
1-butanol | | alkyl alcohol; primary alcohol; short-chain primary fatty alcohol | human metabolite; mouse metabolite; protic solvent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
catechol | | catechols | allelochemical; genotoxin; plant metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent; chelator; food acidity regulator; fundamental metabolite | 1988 | 2012 | 24.0 | low | 0 | 1 | 0 | 0 | 1 | 0 |
gallic acid | | trihydroxybenzoic acid | antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite | 2000 | 2013 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
malic acid | | 2-hydroxydicarboxylic acid; C4-dicarboxylic acid | food acidity regulator; fundamental metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite; Daphnia magna metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
glycine | | alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
glycerol | | alditol; triol | algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydroquinone | | benzenediol; hydroquinones | antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
pyruvaldehyde | | 2-oxo aldehyde; propanals | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 2013 | 2015 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
phytic acid | | inositol phosphate | | 2024 | 2024 | 0.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
niacin | | pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3 | antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent | 1949 | 1949 | 75.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
nitrites | | monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species | human metabolite | 1987 | 2023 | 15.0 | low | 0 | 1 | 0 | 0 | 1 | 1 |
oxalic acid | | alpha,omega-dicarboxylic acid | algal metabolite; human metabolite; plant metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
triphosphoric acid | | acyclic phosphorus acid anhydride; phosphorus oxoacid | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diphosphoric acid | | acyclic phosphorus acid anhydride; phosphorus oxoacid | Escherichia coli metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sulfites | | divalent inorganic anion; sulfur oxide; sulfur oxoanion | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sulfur dioxide | | sulfur oxide | Escherichia coli metabolite; food bleaching agent; refrigerant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
uric acid | | uric acid | Escherichia coli metabolite; human metabolite; mouse metabolite | 1992 | 2000 | 28.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
sk&f-38393 | | benzazepine; catechols; secondary amino compound | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1-anilino-8-naphthalenesulfonate | | aminonaphthalene; naphthalenesulfonic acid | fluorescent probe | 2015 | 2023 | 4.3 | low | 0 | 0 | 0 | 0 | 1 | 2 |
3-methylcholanthrene | | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist; carcinogenic agent | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
p-chloromercuribenzoic acid | | chlorine molecular entity; mercuribenzoic acid | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
p-aminohippuric acid | | N-acylglycine | Daphnia magna metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
theophylline | | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
anthralin | | anthracenes | antipsoriatic | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
antipyrine | | pyrazolone | antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
benzamidine | | benzenes; carboxamidine | serine protease inhibitor | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
caffeine | | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
deferoxamine | | acyclic desferrioxamine | bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ethoxyquin | | aromatic ether; quinolines | antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
carbonyl cyanide p-trifluoromethoxyphenylhydrazone | | aromatic ether; hydrazone; nitrile; organofluorine compound | ATP synthase inhibitor; geroprotector; ionophore | 1981 | 1991 | 38.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
haloperidol | | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ketamine | | cyclohexanones; monochlorobenzenes; secondary amino compound | analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ethylmaleimide | | maleimides | anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
phloretin | | dihydrochalcones | antineoplastic agent; plant metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
spiperone | | aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound | alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
stearic acid | | long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid | algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
hydroxyproline | | 4-hydroxyproline; L-alpha-amino acid zwitterion | human metabolite; mouse metabolite; plant metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
cyanides | | pseudohalide anion | EC 1.9.3.1 (cytochrome c oxidase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sucrose | | glycosyl glycoside | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent | 1954 | 1954 | 70.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
apomorphine | | aporphine alkaloid | alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
galactose | | D-galactose; galactopyranose | Escherichia coli metabolite; mouse metabolite | 2000 | 2005 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
edetic acid | | ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid | anticoagulant; antidote; chelator; copper chelator; geroprotector | 1986 | 2018 | 21.0 | low | 0 | 1 | 0 | 1 | 1 | 0 |
phlorhizin | | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | antioxidant; plant metabolite | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
aniline | | anilines; primary arylamine | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
methionine | | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
histidine | | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
tert-butylhydroperoxide | | alkyl hydroperoxide | antibacterial agent; oxidising agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
acrylamide | | acrylamides; N-acylammonia; primary carboxamide | alkylating agent; carcinogenic agent; Maillard reaction product; mutagen; neurotoxin | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
beta-glucono-1,5-lactone | | aldono-1,5-lactone; gluconolactone | animal metabolite; mouse metabolite | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
quinoxalines | | mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cyclohexanol | | cyclohexanols; secondary alcohol | solvent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
pyrroles | | pyrrole; secondary amine | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
thiophenes | | mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound | non-polar solvent | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
shikimic acid | | alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid; hydroxy monocarboxylic acid | Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
3-o-methylglucose | | D-aldohexose derivative | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
catechin | | catechin | antioxidant; plant metabolite | 1979 | 2010 | 29.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
cyclopentane | | cycloalkane; cyclopentanes; volatile organic compound | non-polar solvent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxazoles | | 1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
pyrazines | | diazine; pyrazines | Daphnia magna metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
hydrazine | | azane; hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
copper gluconate | | organic molecular entity | | 1981 | 1988 | 39.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
myristic acid | | long-chain fatty acid; straight-chain saturated fatty acid | algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
3-hydroxyflavone | | flavonols; monohydroxyflavone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
homoserine | | amino acid zwitterion; homoserine | algal metabolite; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cyclopentenone | | alicyclic ketone; enone | Hsp70 inducer | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
2,6-dichloroindophenol | | dichlorobenzene; quinone imine | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
d-alpha tocopherol | | alpha-tocopherol | algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
2-tert-butylhydroquinone | | hydroquinones | food antioxidant | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
fucose | | fucopyranose; L-fucose | Escherichia coli metabolite; mouse metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
uridine diphosphate glucuronic acid | | UDP-D-glucuronic acid | Escherichia coli metabolite; human metabolite; mouse metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
2,3-diketogulonic acid | | | | 1981 | 1986 | 40.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
mannose | | D-aldohexose; D-mannose; mannopyranose | metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
dithiothreitol | | 1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol | chelator; human metabolite; reducing agent | 1989 | 2000 | 29.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
butylhydroxybutylnitrosamine | | nitrosamine; primary alcohol | carcinogenic agent | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
gold | | copper group element atom; elemental gold | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sodium nitrate | | inorganic nitrate salt; inorganic sodium salt | fertilizer; NMR chemical shift reference compound | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
sodium sulfate | | inorganic sodium salt | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
deuterium oxide | | deuterated compound; water | NMR solvent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ozone | | elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen | antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sodium selenite | | inorganic sodium salt; selenite salt | nutraceutical | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tiletamine hydrochloride | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
tetradecanoylphorbol acetate | | acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester | antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sodium azide | | inorganic sodium salt | antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
azides | | pseudohalide anion | mitochondrial respiratory-chain inhibitor | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
mifepristone | | 3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound | abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
n 0437, (-)-isomer | | tetralins | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
adenosine | | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glucose, (beta-d)-isomer | | D-glucopyranose | epitope; mouse metabolite | 1990 | 2013 | 19.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
aristeromycin | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
neplanocin a | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ethylene diurea | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
homocysteine | | amino acid zwitterion; homocysteine; serine family amino acid | fundamental metabolite; mouse metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
2-methyl-1,4-dinitropyrrole | | | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
2,5-diketogluconic acid | | diketoaldonic acid | Escherichia coli metabolite | 1981 | 1986 | 40.5 | high | 0 | 2 | 0 | 0 | 0 | 0 |
cobalt | | cobalt group element atom; metal allergen | micronutrient | 1949 | 1949 | 75.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
dodecyl-beta-d-maltoside | | disaccharide derivative; glycoside | detergent | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
tris(2-carboxyethyl)phosphine | | phosphine derivative; tricarboxylic acid | reducing agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
galactonolactone | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
hydroxyl radical | | oxygen hydride; oxygen radical; reactive oxygen species | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
dehydroerythorbic acid | | | | 1986 | 2001 | 28.3 | high | 0 | 1 | 1 | 1 | 0 | 0 |
arabinose | | L-arabinose | Escherichia coli metabolite; mouse metabolite | 1995 | 2006 | 24.0 | low | 0 | 0 | 4 | 2 | 0 | 0 |
elastin | | oligopeptide | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ouabain | | 11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone | anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite | 1989 | 2006 | 28.7 | low | 0 | 1 | 1 | 1 | 0 | 0 |
tartaric acid | | tartaric acid | Escherichia coli metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
dehydroascorbic acid | | dehydroascorbic acid; vitamin C | coenzyme; mouse metabolite | 1979 | 2014 | 31.6 | low | 0 | 10 | 8 | 2 | 1 | 0 |
betadex | | cyclodextrin | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
retinol | | retinol; vitamin A | human metabolite; mouse metabolite; plant metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
dactinomycin | | actinomycin | mutagen | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
potassium permanganate | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
glycosides | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
sorbic acid | | alpha,beta-unsaturated monocarboxylic acid; sorbic acid | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
pyrophosphate | | diphosphate ion | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
curcumin | | aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol | anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
nadp | | | | 1991 | 1996 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
valinomycin | | cyclodepsipeptide; macrocycle | antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
laccase | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
quinine | | cinchona alkaloid | antimalarial; muscle relaxant; non-narcotic analgesic | 1946 | 1946 | 78.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
metaphosphoric acid | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sodium dodecyl sulfate | | organic sodium salt | detergent; protein denaturant | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
rutin | | disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone | antioxidant; metabolite | 1979 | 1979 | 45.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
amphotericin b | | antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic | antiamoebic agent; antiprotozoal drug; bacterial metabolite | 1988 | 1989 | 35.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
pulmicort | | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone | anti-inflammatory drug; bronchodilator agent; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
monodehydroascorbate | | organic radical | mouse metabolite | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
oxalates | | | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
pericosine b | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
trans-sodium crocetinate | | | | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ribose | | D-ribose; ribopyranose | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
acid phosphatase | | | | 1988 | 1990 | 35.0 | low | 0 | 2 | 1 | 0 | 0 | 0 |
nad | | organophosphate oxoanion | cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite | 1990 | 1991 | 33.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
sodium hypochlorite | | inorganic sodium salt | bleaching agent; disinfectant | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
sodium bisulfite | | inorganic sodium salt; sulfite salt | allergen; food antioxidant; food colour retention agent; mutagen; reducing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sodium nitrite | | inorganic sodium salt; nitrite salt | antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison | 1988 | 2020 | 17.0 | low | 0 | 1 | 0 | 0 | 2 | 0 |
ascorbic acid | | ascorbic acid; vitamin C | coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent | 1946 | 2023 | 28.7 | high | 3 | 59 | 45 | 26 | 25 | 6 |
glucoascorbic acid | | | | 1949 | 1992 | 53.5 | medium | 0 | 1 | 1 | 0 | 0 | 0 |
ascorbyl monostearate | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ascorbic acid 2-o-glucoside | | glycoside | | 2007 | 2014 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
rifampin | | cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion | angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
methylnitronitrosoguanidine | | nitroso compound | alkylating agent | 1983 | 1985 | 40.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
Adenocarcinoma | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Adenocarcinoma, Basal Cell | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Aging | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Anochlesia | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Anoxemia | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Ascorbic Acid Deficiency | 0 | | 1955 | 2001 | 38.8 | medium | 0 | 5 | 3 | 1 | 0 | 0 |
Benign Neoplasms | 0 | | 1983 | 1984 | 40.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Bladder Cancer | 0 | | 1984 | 1987 | 38.7 | low | 0 | 3 | 0 | 0 | 0 | 0 |
Body Weight | 0 | | 1984 | 1998 | 35.6 | medium | 0 | 6 | 2 | 0 | 0 | 0 |
Cancer of Stomach | 0 | | 1983 | 1985 | 40.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Candida Infection | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Candidiasis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Carcinoma, Epidermoid | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Carcinoma, Squamous Cell | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Cell Transformation, Neoplastic | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cocarcinogenesis | 0 | | 1984 | 1987 | 38.7 | low | 0 | 3 | 0 | 0 | 0 | 0 |
Deficiency, Ascorbic Acid | 0 | | 1955 | 2001 | 38.8 | medium | 0 | 5 | 3 | 1 | 0 | 0 |
Dehydration | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Electrolytes | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Erythrocytosis | 0 | | 1949 | 1949 | 75.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Hyperplasia | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Hypoascorbemia | 0 | | 1955 | 2001 | 44.5 | low | 0 | 3 | 0 | 1 | 0 | 0 |
Hypoxia | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Infections, Plasmodium | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leukemia, Lymphocytic | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Leukemia, Lymphoid | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Malaria | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Neoplasms | 0 | | 1983 | 1984 | 40.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Papilloma | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Papilloma, Squamous Cell | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Pregnancy | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Sarcoma | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Sarcoma, Epithelioid | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Scurvy | 0 | | 1955 | 2001 | 44.5 | low | 0 | 3 | 0 | 1 | 0 | 0 |
Sensitivity and Specificity | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Stomach Neoplasms | 0 | | 1983 | 1985 | 40.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Sunburn | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Urinary Bladder Neoplasms | 0 | | 1984 | 1987 | 38.7 | low | 0 | 3 | 0 | 0 | 0 | 0 |
Reduction of dehydroerythorbic acid in vitamin C-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 47, Issue:4, 2001
Contents of erythorbic acid in the tissues of guinea pigs intraperitoneally administered erythorbic acid.Journal of nutritional science and vitaminology, , Volume: 44, Issue:5, 1998
Vitamin C activity of erythorbic acid in ascorbic acid-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 41, Issue:1, 1995
Comparison of absorption of erythorbic acid and ascorbic acid in guinea pig small intestine.Journal of nutritional science and vitaminology, , Volume: 37, Issue:5, 1991
Ascorbic acid and erythorbic acid metabolism in nonpregnant women.The American journal of clinical nutrition, , Volume: 50, Issue:5, 1989
Effect of erythorbic acid administration on activities of drug metabolic enzyme and phosphatases in guinea pigs administered an adequate amount of ascorbic acid.Journal of nutritional science and vitaminology, , Volume: 35, Issue:2, 1989
Effect of erythorbic acid administration on ascorbic acid content in guinea pig tissues.Journal of nutritional science and vitaminology, , Volume: 32, Issue:2, 1986
HUMAN METABOLISM OF L-ASCORBIC ACID AND ERYTHORBIC ACID.The Journal of nutrition, , Volume: 81, Issue:2, 1963
Biochemical studies on d-araboascorbic acid in vitamin C deficiency.The Journal of vitaminology, , Jul-10, Volume: 1, Issue:3, 1955
Absence of promotion potential for calcium L-ascorbate, L-ascorbic dipalmitate, L-ascorbic stearate and erythorbic acid on rat urinary bladder carcinogenesis.Cancer letters, , Volume: 35, Issue:1, 1987
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Promotion by ascorbic acid, sodium erythorbate and ethoxyquin of neoplastic lesions in rats initiated with N-butyl-N-(4-hydroxybutyl) nitrosamine.Cancer letters, , Volume: 23, Issue:1, 1984
Sodium erythorbate is not carcinogenic in F344 rats.Experimental and molecular pathology, , Volume: 41, Issue:1, 1984
Effect of erythorbate on N-methyl-N'-nitro-N-nitrosoguanidine-induced stomach carcinogenesis in F344 rats.The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, , Volume: 30, Issue:1-4, 1983
Reduction of dehydroerythorbic acid in vitamin C-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 47, Issue:4, 2001
The search for the specific factor in scurvy.Perspectives in biology and medicine, ,Spring, Volume: 24, Issue:3, 1981
The antiscorbutic action of L-ascorbic acid and D-isoascorbic acid (erythorbic acid) in the guinea pig.The American journal of clinical nutrition, , Volume: 34, Issue:1, 1981
Biochemical studies on d-araboascorbic acid in vitamin C deficiency.The Journal of vitaminology, , Jul-10, Volume: 1, Issue:3, 1955
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Effect of erythorbate on N-methyl-N'-nitro-N-nitrosoguanidine-induced stomach carcinogenesis in F344 rats.The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, , Volume: 30, Issue:1-4, 1983
Reduction of dehydroerythorbic acid in vitamin C-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 47, Issue:4, 2001
Contents of erythorbic acid in the tissues of guinea pigs intraperitoneally administered erythorbic acid.Journal of nutritional science and vitaminology, , Volume: 44, Issue:5, 1998
Vitamin C activity of erythorbic acid in ascorbic acid-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 41, Issue:1, 1995
Comparison of absorption of erythorbic acid and ascorbic acid in guinea pig small intestine.Journal of nutritional science and vitaminology, , Volume: 37, Issue:5, 1991
Effect of erythorbic acid administration on activities of drug metabolic enzyme and phosphatases in guinea pigs administered an adequate amount of ascorbic acid.Journal of nutritional science and vitaminology, , Volume: 35, Issue:2, 1989
Ascorbic acid and erythorbic acid metabolism in nonpregnant women.The American journal of clinical nutrition, , Volume: 50, Issue:5, 1989
Effect of erythorbic acid administration on ascorbic acid content in guinea pig tissues.Journal of nutritional science and vitaminology, , Volume: 32, Issue:2, 1986
HUMAN METABOLISM OF L-ASCORBIC ACID AND ERYTHORBIC ACID.The Journal of nutrition, , Volume: 81, Issue:2, 1963
Biochemical studies on d-araboascorbic acid in vitamin C deficiency.The Journal of vitaminology, , Jul-10, Volume: 1, Issue:3, 1955
Absence of promotion potential for calcium L-ascorbate, L-ascorbic dipalmitate, L-ascorbic stearate and erythorbic acid on rat urinary bladder carcinogenesis.Cancer letters, , Volume: 35, Issue:1, 1987
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Promotion by ascorbic acid, sodium erythorbate and ethoxyquin of neoplastic lesions in rats initiated with N-butyl-N-(4-hydroxybutyl) nitrosamine.Cancer letters, , Volume: 23, Issue:1, 1984
Contents of erythorbic acid in the tissues of guinea pigs intraperitoneally administered erythorbic acid.Journal of nutritional science and vitaminology, , Volume: 44, Issue:5, 1998
Vitamin C activity of erythorbic acid in ascorbic acid-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 41, Issue:1, 1995
Effect of graded doses of erythorbic acid on activities of drug metabolic enzyme and phosphatases in guinea pigs.Journal of nutritional science and vitaminology, , Volume: 34, Issue:5, 1988
Erythorbic acid content in tissues of guinea pigs administered erythorbic acid.Journal of nutritional science and vitaminology, , Volume: 33, Issue:3, 1987
Effect of erythorbic acid administration on ascorbic acid content in guinea pig tissues.Journal of nutritional science and vitaminology, , Volume: 32, Issue:2, 1986
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Sodium erythorbate is not carcinogenic in F344 rats.Experimental and molecular pathology, , Volume: 41, Issue:1, 1984
Promotion by ascorbic acid, sodium erythorbate and ethoxyquin of neoplastic lesions in rats initiated with N-butyl-N-(4-hydroxybutyl) nitrosamine.Cancer letters, , Volume: 23, Issue:1, 1984
Absence of promotion potential for calcium L-ascorbate, L-ascorbic dipalmitate, L-ascorbic stearate and erythorbic acid on rat urinary bladder carcinogenesis.Cancer letters, , Volume: 35, Issue:1, 1987
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Promotion by ascorbic acid, sodium erythorbate and ethoxyquin of neoplastic lesions in rats initiated with N-butyl-N-(4-hydroxybutyl) nitrosamine.Cancer letters, , Volume: 23, Issue:1, 1984
Sodium erythorbate is not carcinogenic in F344 rats.Experimental and molecular pathology, , Volume: 41, Issue:1, 1984
Effect of erythorbate on N-methyl-N'-nitro-N-nitrosoguanidine-induced stomach carcinogenesis in F344 rats.The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, , Volume: 30, Issue:1-4, 1983
Reduction of dehydroerythorbic acid in vitamin C-deficient guinea pigs.Journal of nutritional science and vitaminology, , Volume: 47, Issue:4, 2001
The search for the specific factor in scurvy.Perspectives in biology and medicine, ,Spring, Volume: 24, Issue:3, 1981
The antiscorbutic action of L-ascorbic acid and D-isoascorbic acid (erythorbic acid) in the guinea pig.The American journal of clinical nutrition, , Volume: 34, Issue:1, 1981
Biochemical studies on d-araboascorbic acid in vitamin C deficiency.The Journal of vitaminology, , Jul-10, Volume: 1, Issue:3, 1955
Effects of sodium L-ascorbate and related compounds on rat stomach carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine.Cancer letters, , Volume: 29, Issue:3, 1985
Effect of erythorbate on N-methyl-N'-nitro-N-nitrosoguanidine-induced stomach carcinogenesis in F344 rats.The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, , Volume: 30, Issue:1-4, 1983
Safety/Toxicity (2)
Pharmacokinetics (1)
Bioavailability (5)
Article | Year |
Erythorbic acid is a potent enhancer of nonheme-iron absorption. The American journal of clinical nutrition, , Volume: 79, Issue:1 | 2004 |
Effect of smoking on erythorbic acid pharmacokinetics. The British journal of nutrition, , Volume: 89, Issue:5 | 2003 |
The antiscorbutic action of L-ascorbic acid and D-isoascorbic acid (erythorbic acid) in the guinea pig. The American journal of clinical nutrition, , Volume: 34, Issue:1 | 1981 |
Influence of erythorbic acid on ascorbic acid retention and elimination in the mouse. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, , Volume: 53, Issue:3 | 1983 |
Comparison of absorption of erythorbic acid and ascorbic acid in guinea pig small intestine. Journal of nutritional science and vitaminology, , Volume: 37, Issue:5 | 1991 |